Comp Set CORONA ERIS× MANKIND× APLLTD× + ALIVUS + AKUMS + AGARWALEYE + HCG + ADVENZYMES + AARTIPHARM + AARTIDRUGS + JLHL + MARKSANS
In ₹ Crore except Per Share
Latest Annual
CORONA
FY26
ERIS
FY26
MANKIND
FY26
APLLTD
FY26
Peer
Average
Valuation — at last close P/E 67.72× 24.04× 47.64× ◆ 22.28×31.32× +116% P/B 16.79× 3.87× 5.59× ◆ 2.65×4.04× +316% EV/EBITDA 43.06× 15.47× 26.45× ◆ 14.47×18.80× +129% Market Cap ₹12,538 Cr ₹15,091 Cr ₹91,142 Cr ₹15,034 Cr ₹40,422 Cr -69% Growth Revenue CAGR 3Y — ◆ 22.92%17.73% 9.12% 16.59% Revenue CAGR 5Y — ◆ 20.89%— 6.37% 13.63% Net Income CAGR 3Y — 20.06% 13.96% ◆ 25.18%19.73% Revenue YoY (latest Q) 22.16% 12.61% 17.33% ◆ 25.66%18.53% +20% Net Income YoY (latest Q) 15.27% ◆ 39.17%37.67% 12.19% 29.68% -49% Profitability EBITDA Margin 20.91% ◆ 35.79%25.34% 15.23% 25.45% -18% Net Income Margin 13.19% ◆ 20.69%13.57% 9.13% 14.46% -9% Return on Common Equity ◆ 24.79%18.34% 12.49% 12.42% 14.42% +72% Return on Capital Employed ◆ 30.28%15.37% 12.51% 13.88% 13.92% +118% Return on Assets ◆ 15.36%8.99% 6.94% 8.11% 8.01% +92% Credit & Quality Total Debt/Equity ◆ 0.19×0.59× 0.38× 0.24× 0.40× -53% Interest Coverage ◆ 36.67×4.36× 4.27× 8.54× 5.72× +541% Scale — latest FY Revenue / Total Income ₹1,403 Cr ₹3,129 Cr ₹14,278 Cr ₹7,345 Cr ₹8,251 Cr -83% Net Income ₹185 Cr ₹648 Cr ₹1,938 Cr ₹671 Cr ₹1,085 Cr -83% Total Assets ₹1,205 Cr ₹7,366 Cr ₹28,080 Cr ₹8,763 Cr ₹14,736 Cr -92% EPS ₹30.27 ₹45.33 ₹46.35 ₹34.33 ₹42 -28% Book Value per Share ₹122.12 ₹281.78 ₹394.87 ₹288.72 ₹321.79 -62%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › » Latest: FY26 · Consolidated CHART » ALPHA AI » COMP » FA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95% .
